“+o.itemList.length+” “+this.config.text.ariaShown+”
“This.config.text.ariaFermé”
Whitefish, Montana – (Newsfile Corp. – July 29, 2020) – CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network committed to the global legal industries of cannabis, CBD and psychedelic, announced an article on genetic studies in the psychedelic space.
Figure 1: Mydecine Innovations Group Inc.
To see a step in The front of Figure 1, visit: https://orders.newsfilecorp.com/files/6612/60658_8258284e04e859bb_001full.jpg
Recently, it was announced that the director of ebbu studios, Robert Roscow, MA, would leave a hash industry conglomerate for the clinical director of the leading psychedelic startup Mydecine Innovations Group Inc. (CSE: MYCO) (OTC Pink: MYCOF) (FSE: 0NFA) Although the exchange of executives is not unusual in the corporate world, this new workforce restructuring is generating enthusiasm among investors. Here’s why:
Before installing a multimillion-dollar heavyweight (and the world’s largest hash company), Canopy Growth Corp. began as another hard-to-understand Canadian microcapsule action. The acquisition of ebbu LLC for C$429 million is a key thing in Canopy’s explosive growth. Following the announcement of the acquisition of ebbu, Canopy’s percentage value peaked in the company’s history.
The acquisition of ebbu gave Canopy Growth the first mobile pharmacology and hash genome editing laboratories to obtain better cannabinoid functionality and unique isolation formulations that provided Canopy with a gene editing program for cannabinoids and pharmacological and progression studies designed to provide medical and adult consumers with precise delight and delight. Ebbu’s genetic advances have also allowed Canopy Growth to extract up to 10 times the yield of genetically modified ebbu plants.
Roscow played a critical role in developing and running the world’s first cannabis genomic editing lab focused on cannabinoid yield improvement, filed patents, established a cannabis tissue culture lab, and supported Canopy Growth’s drug development team with statistical analysis and experimental design for proprietary formulations.
Now Roscow is helping Mydecine build an ecosystem of resources for the prospecting of fungi for human well-being.
The importance of genetics
Figure 2: Mydecine Innovations Group Inc. To see a step in Front of Figure 2, visit: https://orders.newsfilecorp.com/files/6612/60658_8258284e04e859bb_002full.jpg
Although psilocybin has a wonderful perspective as a healing molecule, very little advances have been made in psilocybin formulas in curative products. The use of fungi as a source of healing medicinal compounds poses two problems.
First, the identity of psilocybin mushrooms would possibly be difficult for others who are not trained in mycology. Second, even known fungi can vary in terms of concentrations of active molecules present. The formulation of exact amounts of natural psilocybin and/or derivatives in capsules, tablets, pills or liquid bureaucracy would eliminate unnecessary disorders resulting from fungal consumption.
Even in maximum potent psychoactive fungi, psilocybin accounts for only 1 to 2% of the total mass. This means that up to 99% of this fungus is made up of other compounds. While many of these compounds would possibly have a healing value of 0, some of them are pharmacologically active, taken or in synergy with known psilocybin derivatives.
Psychedelic fungi involve a cocktail of compounds, some of which cause psychotropic effects in humans. Some of the active compounds in “magic” fungi are psilocybin, psilocin, norpsilocin, beocistine, norbaeocystin and aeruginine.
Like cannabis, researchers are just beginning to perceive the other compounds discovered in psychedelic fungi and even non-psychedelic fungi involving other medicinal compounds. They are tactics to expand psychedelic drugs targeting other patient populations, such as drugs that have no hallucinogenic effects or drugs that prevent a “bad trip” for consumers.
The procedure for creating new psychedelic drugs comes to the research of existing literature and the design of new analogues or structures similar to the compound. For example, researchers can read about how psilocybin targets receptors in the brain and expand other structures designed to also target the same receptors to produce an express effect.
Gw prescription drugs for psychedelics
In the multibillion-dollar arms race in the pharmaceutical industry, researchers are looking for new healing applications. Even a single app can be worth billions of dollars on its own. Specific example: GW Pharmaceuticals.
The London-based pharmaceutical company makes Epidiolex, the world’s only cannabinoid-based FDA approved drug. Since the U.S. Food Administration approved Epidiolex for use in 2018, the company’s quarterly revenue has skyrocketed from around $7 million to more than $120 million, the vast majority of which ($116.1 million) comes from Epidiolex sales.
Like GW Pharmaceuticals in the cannabinoid market, Mydecine Innovations Group Inc. leads the progression of psychedelic drugs and healing responses and has already begun studies and efforts to progress in the mycology picture.
Figure 3: Mydecine Innovations Group Inc. To see a step forward from Figure 3, visit: https://orders.newsfilecorp.com/files/6612/60658_8258284e04e859bb_003full.jpg
As cSO, Roscow now oversees study projects at Mydecine’s lab in Denver, Colorado. This includes the study, variety and cultivation of rare and exotic valuable fungi, as well as the incorporation of leading analytical chemistry, molecular biology, next-generation sequencing and tissue culture.
“The diversity of medical prospective in fungal compounds is astonishing, the synergy of this wisdom with complex studies and production presents a remarkable opportunity for progress in the complex remedy of serious situations as well as in general well-being,” Roscow said.
Looking
Ongoing studies indicate that the chemical compound psilocybin is useful in treating genius disorders, adding depression, anxiety, compulsive disorder, substance abuse and post-traumatic stress disorder. However, there are many other compounds in fungi that offer the option of many other discoveries.
The true perspective of fungi is still unknown, as additional studies are still needed to fully integrate all of its benefits into the customer market. As in the past, Roscow and his team have the ability to do the mandatory studies and make new discoveries to create more valuable properties, and Mydecine is about to reap the benefits.
About CFN Enterprises Inc.
CFN Enterprises Inc. (OTCQB: CNFN) is a virtual media and e-commerce corporation aimed at promoting businesses and brands in highly regulated emerging industries around the world. CFN connects investors with new market opportunities while helping consumers locate cutting-edge products that their lives. Learn more about www.cfnenterprisesinc.com.
CFN Enterprises Media Contact Inc.:
CFN Enterprises Inc. – 001 (833) 420-CNFN [email protected]
Corporate communication:
Josh Bartch, CEO, [email protected]
Public Relations:
Cynthia [email protected]
To view the original edition of this press release, https://www.newsfilecorp.com/release/60658